Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

 Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

Shots:

  • The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks.
  • The P-IIIb/IV SPIRIT-H2H study results: met its 1EPs & 2Eps i.e, @24wks. reduction by 50% in disease activity as defined by ACR50; PASI100 (36% vs 28%) & superior to Humira, ACR50 (51% vs 47%); PASI100 (60% vs 47%) respectively, will be presented at EULAR
  • Taltz is a mAb targeting IL-17A cytokine, act by inhibiting its interaction with the IL-17 receptor which is involved in inflammatory and immune responses and inhibits the release of pro-inflammatory cytokines and chemokines

Click here to read full press release/ article | Ref: Eli Lilly | Image: Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post